Drug intelligence / Profile preview

KW-6500

Development stage: Phase 3
Lead developer: Kyowa Kirin
Modality: Small Molecules
Administration: Subcutaneous

Overview

KW-6500 is an investigational drug under development by Kyowa Hakko Kirin for the treatment of Parkinson's disease-related motor complications, specifically hypanakinesia. It is a D2 agonist administered subcutaneously. KW-6500 has been granted an orphan drug designation and has completed Phase 3 clinical trials.

Brand names: Apomine
Other names: Apomorphine hydrochloride hydrate

Targets

DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)5-HT (Serotonin receptors)ADRA1A (α1A)

Beyond the preview

Go deeper on KW-6500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KW-6500.